Our Focus
Our FORCE
TM
Platform
Pipeline
About Us
Investors & Media
Careers & Culture
DM1
DMD
FSHD
FORCE
TM
Platform
Scientific Publications & Presentations
Supporting Literature
Overview
Programs
Overview
Leadership
Board of Directors
Scientific Advisory Board
Contact Us
Company Overview
News & Events
Stock Information
Corporate Governance
Financials & Filings
IR Resources
Our Culture & Values
Employees Speak
Competitive Benefits
Open Positions
Stay in Touch
info@dyne-tx.com
781.786.8230
The power to target muscle to
stop or reverse disease progression
Scientific Publications & Presentations
May 12, 2020
Targeted Delivery of ASOs Demonstrates Potential to Treat Duchenne Muscular Dystrophy
Presented at ASGCT 2020
Supporting Literature
Platform
Development of Antibody-siRNA Conjugate Targeted to Cardiac and Skeletal Muscles
Journal of Controlled Release
Metabolic Catastrophe in Mice Lacking Transferrin Receptor in Muscle
EBio Medicine
DM1
Targeting Nuclear RNA for In Vivo Correction of Myotonic Dystrophy
Nature
Identification and Characterization of Modified Antisense Oligonucleotides Targeting DMPK in Mice and Nonhuman Primates for the Treatment of Myotonic Dystrophy Type 1
Nucleic Acids Research (NAR)
In Situ Fluorescence Analysis Demonstrates Active siRNA Exclusion From the Nucleus by Exportin 5
Nucleic Acids Research (NAR)
RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus
Molecular Therapy
The Current State and Future Directions of RNAi-based Therapeutics
Nature Reviews Drug Discovery
Quantitative Fluorescence Imaging Determines the Absolute Number of Locked Nucleic Acid Oligonucleotides Needed for Suppression of Target Gene Expression
Nucleic Acids Research (NAR)
Cellular Localization of Long Non-Coding RNAs Affects Silencing by RNAi More Than by Antisense Oligonucleotides
Nucleic Acids Research (NAR)
RNAi Factors Are Present and Active in Human Cell Nuclei
Cell Reports
RNA-mediated Therapies in Myotonic Dystrophy
Drug Discovery Today
DMPK Gene Deletion or Antisense Knockdown Does Not Compromise Cardiac or Skeletal Muscle Function in Mice
Human Molecular Genetics
FSHD
Morpholino-Mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics
Molecular Therapy
Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy (FSHD)
Genes